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ABSTRACT 
 
Obesity is a globally increasing disease particularly in developing countries and 
among children. It is mainly caused by intake of diets high in fat and the lack of 
physical activity. Obesity is a risk factor for diseases such as type II diabetes, high 
blood pressure, high cholesterol and certain cancers. Prediabetes is a condition where 
blood glucose levels are above normal but have not reached those of diabetes. It is 
difficult to diagnose, as there are no signs or symptoms. Some type II diabetes 
patients bear no symptoms at all and the disease is discovered late. Proteomics is a 
field that can provide opportunities for early diagnosis of diseases through biomarker 
discovery. The early diagnosis of diabetes can assist in the prevention and treatment 
of diabetes. Therefore there is a need for the early diagnosis of diabetes. 
 
Twenty Wistar rats were used. The rats were initially fed a CHOW diet, which is the 
standard balanced diet for rats, for 4 weeks. The rats were then divided into 2 groups 
of 10 where 1 group was fed CHOW and another was fed a high fat (HF) diet in order 
to induce obesity. The two groups were fed their respective diets for 18 weeks. Rats 
were weighed. Rats were placed in metabolic chambers and 24 hour urine samples 
were collected. Ketone levels were measured by Ketostix. Urine proteins were 
precipitated by acetone, quantified and separated on both the 1D SDS-PAGE and the 
2D SDS-PAGE. Protein expression changes between CHOW and HF fed rats were 
determined and identified using MALDI-TOF mass spectrometry. Protein spots 
intensities increased and decreased between the CHOW and HF fed rats. Transducin 
(beta)-like 3 was identified as the only differentially expressed protein, which might 
serve as a potential biomarker for prediabetes. 
 
 
Key words:  Obesity, type II diabetes, prediabetes, biomarker discovery, proteomics, 
high fat diet, 1D SDS-PAGE, 2D SDS-PAGE, urine, mass spectrometry 
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1.1. INTRODUCTION 
 
 
Obesity has reached epidemic proportions in developed countries. The prevalence of 
obesity in developing continues to increase at an alarming rate worldwide (Hill and 
Peter, 1998). The World Health Organisation (WHO) has classified approximately 1.6 
billion people worldwide as overweight and over 400 million people as obese (WHO, 
2006b), and  South Africa is not spared from this epidemic. A report released in 1998 
showed that 57 % of women and 29 % of men across all ethnic groups being regarded 
as overweight and obese (Puoane et al., 2002).  
 
Obesity can result from mutations at genetic level. However, in recent times the 
environment has influenced the increase in obesity development with increased 
consumption of diets high in fat, lack of exercise, increased appetite and to some 
extent eating disorders, in particular binge eating (Hill, 2006). The increased trend in 
obesity has been associated with increased consumption of high-fat foods (fast foods) 
(Jeffery and French, 1998).  
 
Obesity is a risk factor for hypertension, atherosclerosis and type II diabetes among 
other diseases (Rao et al., 2007; Teasdale et al., 2007). In some cases, death results. 
The increase in obesity has consequently led to an increase in the prevalence of type 
II diabetes (WHO, 2006b). According to WHO, approximately 85% of people with 
diabetes are type II, and of these, 90% are obese or overweight (WHO, 2003). 
Approximately 3.2 million deaths every year are due to complications of diabetes 
(Unwin and Marlin, 2004).  
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Some type II diabetes patients bear no symptoms at all and the disease is discovered 
late, which makes diabetes is a public health problem that if left untreated and result 
in complications. More often patients present with end stage complications, such as 
diabetes nephropathy, kidney disorders, heart disorders and retinopathy. At this point, 
most of the damages caused are irreversible.   
 
Current methods for diagnosis of disease include diagnosis from symptoms, blood 
tests that measure antibodies and glucose levels, and urine dipsticks that detect nitrite, 
ketones, glucose and proteins produced during diseases. Although these methods are 
reliable for diagnosing late stages of diseases, they produce false negative diagnoses 
in patients with early stages of diseases. The late discovery or diagnosis of diseases 
leads to late delivery of treatment, resulting in end stage complications and death.  
 
The increase in obesity-associated diseases and mortalities has increased the urgency 
for the development of technologies that are quick, simple and can diagnose the early 
stages of diseases. The early diagnosis of diseases would allow for the proper 
monitoring of diseases and early efficient delivery of treatment for diseases.  
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1.2. OBESITY 
 
1.2.1 Defining overweight and obesity 
 
Obesity, also known as adiposity, is an excess accumulation of fat mass in the body. 
Obesity is principally described as the imbalance that results when energy intake 
exceeds the energy expenditure (Trayhurn, 2004). That is, when the energy intake 
equals the energy expenditure then energy is balanced and the body fat is stable (Hill, 
2000). The accumulation of high-energy intake favours lipid storage leading to an 
increase in the number and the size of the fat-storage cells known as adipocytes which 
are found in the adipose tissue (Loos and Bouchard, 2003). Thus increasing the fat 
mass and ultimately leading to weight gain. Obesity has also been defined as the 
expansion of white fat mass (Trayhurn, 2004). At the same time, the adipose tissue is 
regarded as the source of endocrine signals particularly in the regulation of energy 
balance (Trayhurn, 2004). 
 
1.2.2 Body Mass Index (BMI) 
 
Adiposity is difficult to characterize and as such there are several measures used to 
determine adiposity. Some of the measurements used are the waist-to-hip ratio, the 
body mass index (BMI), skinfold thickness ratio and waist circumference. However, 
BMI is a common assessment method used in determining the prevalence of 
overweight and obesity.  
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Table 1. 1 Cut-off points proposed by WHO expert committee for the classification of 
overweight   and obesity 
Adapted from (Kopelman, 2000) 
BMI (kg.m
-2
)   WHO classification  Popular description 
<18.5    Underweight   Thin 
18.5 – 24.9    -   ‘Healthy’, ‘normal’ 
25.0 – 29.9   Grade 1 overweight  Overweight 
30.0 – 39.9   Grade 2 overweight  Obesity 
!40.0    Grade 3 overweight  Morbid obesity 
 
 
BMI is a common and convenient formula that is used to measure body fatness as it 
uses height and weight. BMI is the quotient of body weight in kilograms and the 
square of the height in meters (Gallagher et al., 1996). BMI scores as proposed by the 
World Health Organisation (WHO) are outlined in table 1.1 above. WHO has 
categorised BMI scores into 5 groups. The first group has a BMI less than 18.5 kg/m
2
 
and is classified as underweight. The second group has BMI scores between 18.5 and 
24.9 kg/m
2
 and is classified as the ‘normal’ acceptable range or a healthy BMI. The 
third group being the overweight group with BMI scores between 25 and 29.9 kg/m
2
. 
The fourth group is defined as the obesity group, with BMI scores 30 kg/m
2
 and 
above. The fifth group with BMI scores 40 kg/m
2
 and higher is defined as the morbid 
obesity group (Kopelman, 2000; WHO, 2006b). 
 
However, BMI has been reported to inaccurately reflect body fatness since it does not 
take into account muscularity and body density (Spataro et al., 1996). Also, BMI is 
considered to be less accurate than the skinfold thickness ratio method that measures 
the skin thickness (Spataro et al., 1996). BMI is not a recommended method in the 
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assessment of body fatness in children as BMI scores in children change with age and 
sex (Wildhalm et al., 2001). 
 
High BMI scores are not only associated with obesity, but they have been correlated 
with a number of human cancers. A 2006 report by the WHO showed that high BMI 
scores increase the risk of the different forms of cancers including breast, colon, 
prostrate, kidney, gall bladder and endometrium (Renehan et al., 2008). 
 
1.2.3 Causes of obesity 
 
1.2.3.1 Genetics 
 
Several studies have shown that mutations, genetic disorders and genetic make-up or 
heredity play a role in the development of obesity. For instance, Prader-Willi 
syndrome, a genetic disorder caused by imprinting of genes on chromosome 15 
increases appetite (Loos and Bouchard, 2003). This is caused by the hyper-secretion 
of a hormone, ghrelin, which stimulates hunger.  
 
In some instances, obesity is influenced by the interplay between genetics and a slew 
of other factors such as the social and cultural environment (Barsh et al., 2000; Hill 
and Peter, 1998; Naggert et al., 1997). This has been illustrated through studies on 
animal models, and monozygotic and dizygotic twins and adoption studies, where 
differences in the body weight can be noted among individuals (or animals) living in 
the same environment (Barsh et al., 2000; Eikelis and Esler, 2005; Hill and Peter, 
1998; Naggert et al., 1997). 
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Spontaneous mutations in the leptin and leptin receptor genes, have been found to 
play a role in the regulation of energy balance thereby causing obesity (Loos and 
Bouchard, 2003). Zhang and co-workers isolated the obesity (ob) genes using 
positional cloning technologies and found that ob genes appeared to encode a 
signalling factor produced by the adipose tissue and released into the bloodstream for 
the regulation of body weight (Zhang et al., 1994). The location of the obesity genes 
on chromosomes can be seen in figure 1.1. 
 
 
Figure 1. 1 Chromosomal location of obesity genes.  
Ideogram of human karyotype with loci for Prader–Willi Syndrome (PWS), Albright 
hereditary osteodystrophy (AHO), Bardet–Biedl Syndrome (BBS) (green line), 
monogenic mutations (green triangle), selected obesity candidate genes (red triangle) 
and QTLs identified by genome-wide linkage scans (red line). Adapted from (Loos 
and Bouchard, 2003). 
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1.2.3.2 Dietary intake 
 
Dietary intake is central in the development of obesity. Macronutrients that provide 
energy are the carbohydrates, fats and proteins. These are balanced by oxidation or 
storage of the different nutrient (Jéquier and Tappy, 1999). Alcohol, ethanol in 
particular, has been implicated as another macronutrient that provides energy (Suter, 
2000). Moderate alcohol intake leads to ethanol metabolism whereas excessive intake 
leads to the decrease in lipid oxidation (Suter, 2000). Thus alcohol ingestion can be 
considered as a risk factor for obesity development. 
 
Changes or shifts in dietary patterns have also been observed, with an increase in diets 
high in fat. These shift in dietary patterns are evident through the preference and high 
consumption of fast foods (Stender et al., 2007). An American population study on 
Coronary Artery Risk Development In young Adults (CARDIA), indicated that fast 
foods have a high fat content and are made available in bigger portions (Stender et al., 
2007).  
 
A high carbohydrate diet has been shown to promote carbohydrate oxidation and a 
high fat diet to stimulate fat storage (Jéquier and Tappy, 1999). These diets high in fat 
therefore promote low fat oxidation causing the accumulation of fat in the adipose 
tissue leading to the development of obesity. 
 
 
 
 
 
 
 
 
  
 9 
    
 
1.2.3.3 Appetite and eating disorders 
 
Appetite can be felt as hunger, leaving individuals yearning for food. Appetite is 
regulated by the digestive tract, adipose tissue and the brain (Neary et al., 2004). This 
has been demonstrated through animal model studies (rodents in particular) in the 
discovery of leptin, an adipose tissue hormone that decreases food intake and loss of 
weight (Wren et al., 2001). 
 
In addition through animal studies, ghrelin, a digestive tract hormone, has been shown 
to increase food intake, weight gain and ultimately cause obesity (Tschop et al., 2000; 
Wren et al., 2001). Ghrelin levels have been shown to be elevated during fasting 
(Neary et al., 2004). 
 
In the regulation of body weight, Wren and coworkers have suggested ghrelin and 
leptin to possibly be part of the vital feedback system (Wren et al., 2001).  The study 
revealed that ghrelin levels decreased in lean individuals following food intake. 
However, following food intake in obese individuals, there was no decrease in the 
ghrelin levels (English et al., 2002). The study further suggested that the absence or 
decreased ghrelin levels indicated impaired suppression of food intake, which could 
result in increased food consumption and weight gain. Thus indicated that food intake 
failed to suppress ghrelin levels in obese individuals, thereby increasing obesity and 
its associated diseases.  
 
Eating disorders are defined as the disturbance of eating habits or weight-control 
behaviours that can result in the impairment of physical health and psychological 
functioning (Fairburn and Harrison, 2003). Three types of eating disorders have to 
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date been identified, namely, anorexia nervosa, bulimia nervosa and binge eating 
disorders. Individuals with anorexia and bulimia nervosa have a tendency to over-
assess their shape, weight and are on the contrary usually used by obese individuals to 
‘control’ their weight (Fairburn and Harrison, 2003).  
 
However, binge eating disorders are characterised by uncontrolled overeating without 
extreme weight-control behaviours, such as vomiting or excessive use of laxatives 
(Hill, 2006). These over eating episodes may results in increased energy intake. This 
will thus lead to the development of obesity. 
 
1.2.3.4 Lack of activity 
 
Change is not only observed in dietary patterns but also in the social environment of 
an individual. The advent of technology, especially in the developed world has 
promoted a sedentary lifestyle in many people. The environment is enriched by the 
improvements in technology such as, televisions, computers, electronic games and 
transportation (Hill and Peter, 1998). These require a great time in an inactive (sitting) 
position. A sedentary lifestyle is characterised by low levels of physical activity and 
thus associated with increased risk of obesity development (Hill and Peter, 1998). 
 
1.3. OBESITY AS A RISK FACTOR 
 
Obesity may lead to the impairment of health by increasing the risk of type II 
diabetes, sleep apnea, atherosclerosis, osteoarthritis, hypertension, coronary artery 
diseases, osteoarthritis, stroke, respiratory problems and other forms of cancer (Rao et 
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al., 2007; Teasdale et al., 2007). Obesity has also been shown to be the risk factor for 
the development of eating disorders such as bulimia nervosa, where overweight 
children or adolescents are tempted to disturb their eating habits in order to lose 
weight (Hill, 2006). In some cases these obesity-related diseases are fatal. 
 
Described below are the common diseases associated with overweight and obesity. 
 
1.3.1 Type II Diabetes 
 
Insulin is important in the adipocyte biology as it detects glucose in the bloodstream. 
It causes the absorption of glucose by the skeletal muscle cells, hepatic cells and 
adipocytes, and storing it in a form of glycogen in the liver and muscle (Khan and 
Flier, 2000). Hence, insulin promotes adipocyte triglyceride stores and results in the 
discontinuation of fat as an energy source. The resistance to the effects of insulin on 
the metabolism of glucose, the uptake of glucose and the storage of glucose is termed 
insulin resistance (Khan and Flier, 2000). Excess glucose in the bloodstream due to 
insulin resistance is characteristic of Type II diabetes (Scott et al., 2005).  
 
1.3.2 Hypertension 
 
Hypertension is closely related to renal dysfunction and obesity as hypertensive 
patients are either overweight or obese (Ribstein et al., 1995). Hypertension is 
associated with the excretion of sodium salts in the urine caused by natriuretics or the 
arterial pressure on sodium excretion known as pressure natriuresis (Hall, 2003). The 
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study further showed that impaired pressure natriuresis accompanies high blood 
pressure as a result of obesity. 
 
Furthermore, the study revealed that obesity is a predictor for hypertension 
development through weight gain and raising blood pressure. Hence, essential 
hypertension develops as a result of renal function alteration and blood pressure is 
increased when weight is gained (Hall, 2003). The exact mechanism that causes 
obesity to raise blood pressure is not understood. A relationship has thus been 
established between hypertension, insulin resistance and abnormal lipid profile 
(Steinberger and Daniels, 2003). 
 
1.3.3 Renal Diseases 
 
The long-term effects of obesity on the kidneys have been shown through glomerular 
hyperfiltration in diabetes studies. Glomerular hyperfiltration rate is a process where 
the glomerular filtration rate increases as a result of increased glomerular capillary 
pressure and is increased in type II diabetes patients (Jong et al., 2002). It has also 
been noticed that obesity and diabetes have similar effects on the kidney causing renal 
damage. Glomerular hyperfiltration is a characteristic of diabetic nephropathy. The 
increase in glomerular filtration rate leads to increased albumin excretion in the urine 
resulting in microalbuminuria (Jong et al., 2002). The glomerular filtration rate then 
falls as a result of excessive albumin excretion leading to noticeable proteinuria and 
ultimately end-stage renal failure known as diabetic nephropathy.  
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However, microalbuminuria is not the only predictor of renal failure, obesity, 
hypertension and complications of diabetes also result in renal damage and ultimately 
renal failure. 
 
1.4. DIABETES MELLITUS 
 
Diabetes is a disease characterised by hyperglycaemia (high glucose levels) as a result 
of impaired insulin production or impaired tolerance to its effects ("Report of the 
expert committee on the diagnosis and classification of diabetes mellitus," 2002). 
Diabetes is a public health problem that is growing subsequent to the increasing 
obesity prevalence. In 2000, diabetes mellitus affected 171 million people worldwide. 
WHO estimates that currently more than 180 million people worldwide are living 
with diabetes while it is estimated that in 2030, 366 million people will be diabetic. 
Figure 1.2 demonstrates the world map of diabetics in developed and developing 
countries. The map also highlights countries with the most diabetics.  
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Figure 1. 2 World map of people with diabetes in developed and developing 
countries  
(WHO, 2006a) 
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1.4.1 Types of diabetes 
 
Diabetes is categorised into 4 groups namely, type I diabetes mellitus, pre-diabetes, 
type II diabetes mellitus and gestational diabetes. The overall symptoms include 
excessive excretion of urine, hunger, thirst, fatigue and weight loss (WHO, 2006a). In 
its advanced stages, diabetes can lead to limb amputations, stroke, blindness and 
kidney failure. 
 
Type I diabetes results from immune-mediated destruction on insulin-producing islet 
beta cells.  
 
Prediabetes is usually characterized by the elevation in blood glucose levels, often 
when the blood glucose levels are above normal but have not reached those of 
diabetes. It’s difficult to diagnose, as there are no signs or symptoms. However people 
with prediabetes have the same complications with type II diabetic people (WHO, 
2006a). People with prediabetes are at high risk of developing type II diabetes. 
 
Type II diabetes is associated with lack of activity and family history of the disease. 
Type II diabetes is characterised by excess glucose in the bloodstream due to insulin 
resistance (Scott et al., 2005). Initially the pancreatic beta cells increase the insulin 
production, resulting in the B-cells been worn out. The worn out beta cells together 
with insulin resistance and impaired insulin secretion lead to the reduction of insulin-
mediated glucose uptake in muscle and adipocytes (Bailey, 2000). Type II diabetes is 
a disease that typically affected adults over the ages of 40 years but with the increase 
in obesity, people of younger ages are also affected by the disease (Nolan, 2006; 
Steinberger and Daniels, 2003).  
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1.4.2 Diabetes diagnosis 
 
Determining or measuring the amount of glucose in the blood diagnoses diabetes.  
This is done through the determination of the fasting plasma glucose (FPG) and an 
oral glucose tolerance test. However, urine properties can also be determined. 
 
1.4.2.1 Oral Glucose Tolerance Test (OGTT) 
 
This test is often used in the diagnosis of prediabetes and diabetes. Blood glucose 
levels are measured after an 8-10 hour fast. Following this, a person is given 75 g of 
glucose in a form of a sweet drink. The blood glucose levels are measured at baseline 
(FPG) and two hours following the intake of glucose. Results are uncertain for 
diabetes and impaired glucose tolerance if the 2 hour plasma glucose is not measured 
(WHO, 2006a). Table 1.2 outlines the WHO criteria for diagnosing diabetes and 
prediabetes.  
 
The impaired glucose tolerance and the impaired fasting glucose are an intermediate 
stage of diabetes mellitus. The glucose levels resulting are above normal and yet 
below the diagnostic level of diabetes, a stage often described as prediabetes. 
 
There is however insufficient data to accurately define normal glucose levels 
(Puavilai et al., 1999). The prediabetes glucose levels differ between WHO and the 
American Diabetic Association (ADA). In 2003, ADA decided to reduce the 
prediabetes glucose levels from 6.1 mmol/L to 5.6 mmol/L (WHO, 2006a). 
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Table 1. 2 A summary of the diabetes diagnostic criteria according to 
WHO. 
Adapted from (WHO, 2006a) 
Diabetes    
Fasting plasma glucose  ! 7.0 mmol/L (126mg/dL) 
2 hour plasma glucose
*
 ! 11.1 mmol/L (200mg/dL) 
Impaired Glucose Tolerance (IGT)   
Fasting plasma glucose  < 7.0 mmol/L (126mg/dL 
2 hour plasma glucose
*
 ! 7.8 and < 11.1 mmol/L (140 mg/dL and 
200mg/dL) 
Impaired Fasting Glucose (IFG)    
Fasting plasma glucose  6.1 to 6.9 mmol/L (110 mg/dL to 125 mg/dL) 
2 hour plasma glucose
*
 < 7.8 mmol/dL (140 mg/dL) 
 
*
 Venous plasma glucose 2 hour after ingestion of 75g oral glucose load 
 
1.4.2.2 Urine dipsticks 
 
These dipsticks are plastic strips attached with several reagent areas to provide tests 
for various analytes including pH of the urine, protein, glucose, ketones, leukocytes, 
nitrites, urobilinogen, specific gravity and bilirubin. 
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1.5. PROTEOMICS 
 
1.5.1 Defining Proteomics 
 
Proteomics is the study of the proteome, and the proteome is defined as the protein 
complement of the genome and often referred to as functional genomics (Scott et al., 
2005). Figure 1.3 illustrates the central dogma of biology, which is the transcription 
of DNA to RNA, and the translation of RNA to proteins.  The proteome is reported to 
change over time in response to different situations (Fliser et al., 2007). The complex 
dynamic nature of the proteome due to post-translational modifications (PTM) has 
created the field of proteomics to be challenging (Scott et al., 2005). 
 
Figure 1. 3 Central dogma indicating the relationship between the genome, 
transcriptome and the proteome (Lam et al., 2006) 
 
Proteomic techniques date back to the mid 1970s with the introduction of two-
dimensional (2D) gel electrophoresis technique by O’Farrell and Klose (Sperling, 
2001).  However, since the completion of the human genome project, proteomics has 
become a field of interest (Khan and Packer, 2006). It is believed by scientists that 
proteomics can reveal proteome changes in biological fluids. Hence, proteomics has a 
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potential of providing strategies for early diagnosis (through diagnostic marker 
discoveries) and new therapeutic targets for the treatment of disease (Hanash, 2003; 
Lam et al., 2006; Scott et al., 2005). 
 
There are many techniques used in the analysis of the proteome. Among them being 
the techniques for structural proteomics (nuclear magnetic resonance and X-ray 
crystallography) and for interaction proteomics (yeast two-hybrid and ligand chips). 
This particular review focuses on expression proteomics. The expression proteomics 
can help with the identification of expressed proteins in relative samples. 
Technologies used in expression of proteomics include 2D sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis (PAGE), protein chips and mass 
spectrometry (Klein and Thongbookerd, 2004; Roelofsen et al., 2007; 
Thongboonkerd et al., 2003). 
 
The principles of the expression proteomics are based firstly on the separation of 
(extracted) proteins by gel electrophoresis on 2D SDS PAGE. The 2D 
electrophoresis-based technology has been reported to be the most powerful tool 
when resolving complex protein mixtures from biological samples (Alaiya et al., 
2003). Furthermore, its ability to differentiate post-translationally modified proteins 
have also been reported (Janech et al., 2007).  
 
An important component for proteome analysis is sample preparation. The principles 
entail inhibition of interfering compounds such as lipids, ionic detergents and nucleic 
acids that could interfere with 2D electrophoresis, and proper protein solubilization 
(Alaiya et al., 2003; Lam et al., 2006; Merrell et al., 2004). Another important aspect 
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of proteome analysis is reproducibility as it is useful in diagnostic applications (Fliser 
et al., 2007; Merrell et al., 2004).  
 
The first dimension is concerned with separation based on charge according to the 
isoelectric (IE) point, whereas the second dimension is concerned with separation 
based on the molecular mass (Scott et al., 2005).  
  
The 2D gel is then stained with an appropriate dye in order to visualise and analyse 
‘spots’ which indicate protein patterns. Relatively high intensity stained ‘spots’ are 
selected, excised from the gel and digested by trypsin (Khan and Packer, 2006). This 
is done in preparation for mass spectrometric analysis which then determines the mass 
list of the peptides.  
 
According to Aebersold and Mann, a mass spectrometer consists of an ion source, a 
mass analyzer that measures the mass-to-charge (m/z) ratio and a detector to register 
the number of ions at each m/z value (Aebersold and Mann, 2003). The most 
commonly used techniques to volatize and ionize proteins or peptides for mass 
spectrometric analyses are the electrospray ionization (ESI) and the matrix-assisted 
laser desorption ionisation (MALDI). The peaks from the mass list are then matched 
on the database for protein sequences in the identification of the proteins. Figure 1.4 
illustrates the mass spectrometry-based proteomics, as it would be carried out in a 
typical experiment. 
It can thus be said that the use of 2-D SDS PAGE in combination with the mass 
spectrometry are used to identify and characterise proteins (Thongboonkerd et al., 
2003).  
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Figure 1. 4 A typical mass spectrometry-based proteomics experiment 
In 1, proteins are fractionated and then separated on an SD-PAGE. In 2, spots of 
interest are then excised and digested by trypsin in preparation of mass spectrometric 
analysis in 3. The peaks from peptide masses are generated in 4 and then matched on 
the database for protein sequence generation as in 5. Adapted from (Aebersold and 
Mann, 2003). 
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1.5.2 Urinary proteomics in the discovery of diabetes biomarkers 
 
With the completion of the Human Genome Project, the focus has since shifted 
towards understanding the function and structure of the human genome through the 
identification of post-translational modifications (PTM), differential expression, 
protein structure and protein-protein interactions (Sinha et al., 2007). Proteomics has 
been reported to play a significant role in clinically useful applications through the 
study of changes in protein expression level or PTM (Vidal et al., 2005). These 
protein changes highlight the role of peptides as potential biomarkers.  
 
Biomarkers are biological indicators that are used to measure a particular state or 
progression of diseases (Rifai et al., 2006). The highly employed strategy in the 
discovery of biomarkers is the top-down proteomics strategy. This strategy involves 
the separation of proteins by 2D electrophoresis, multidimensional chromatography or 
capillary electrophoresis followed by tryptic digestion of isolated proteins and the 
analysis of the resulting peptides by mass spectrometry. Biomarkers are used in the 
understanding of disease pathogenesis, the early detection of diseases through 
diagnostic tools, potential drug targets in the treatment of diseases and monitoring the 
response to therapy (Hanash, 2003; Lam et al., 2006; Scott et al., 2005; Vidal et al., 
2005). 
 
Polypeptides in body fluids are relatively accessible for example saliva, cerebrospinal 
fluid, serum, blood and urine (Miller et al., 2006; Theodorescu and Mischak, 2007; 
Wait et al., 2001). Thus body fluids are considered interesting biomarker sources for 
diagnostic purposes. Urine is an easily accessible body fluid that contains complex 
mixtures of proteins (Roelofsen et al., 2007; Theodorescu and Mischak, 2007). Owing 
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to the latter factor, urine is thus considered as an interesting source of biomarkers. 
Urine can also be obtained non-invasively as compared with other body fluids such as 
blood and cerebrospinal fluids, and that it is plentiful (Hortin and Sviridov, 2007). 
Urinary proteins are also reported to be stable and to undergo insignificant proteolysis 
within several hours after collection (Theodorescu and Mischak, 2007). This stability 
of the proteins also favours urine as an interesting source of biomarkers as it can be 
stored for several years at -20 °C without significantly altering the proteome. 
 
Urinary proteins have been studied since the 1970s. A study by Anderson and 
colleagues reported that the human urine contains trace amounts of proteins and some 
of them diagnostically useful (Anderson et al., 1979). The study further identified 
types of proteins found in urine. The types included normal plasma proteins, proteins 
released into the urine from the kidney, proteins reaching the urine after its formation 
in the kidney, proteins leaked from tissues outside the urogenital tract, hormones or 
other signal substances, substances released by the products of conception, tumour-
associated substances and products of bacterial or viral infections. 
 
Urine proteins originate from ultrafiltration of plasma and from the urinary tract itself 
(Gonza"lez-Buitrago et al., 2007). As a result, urine contains protein components 
similar to those found in the blood. Urine is also considered to contain dilute protein 
concentrations, high salt content and proteins of low molecular weight (LMW) (< 30 
kDa) (Gonza"lez-Buitrago et al., 2007; Khan and Packer, 2006; Theodorescu and 
Mischak, 2007). This high salt content can interfere with the isoelectric focusing of 
proteins during 2D electrophoresis as it tends to bind to protein surfaces to make them 
less isoelectric.  
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Salt is however not the only concern in urine protein analysis. A major concern is the 
removal of albumin and other abundant proteins. However the removal of albumin 
and other abundant proteins has been associated with the loss or removal of LMW 
proteins. The removal of salt and the high abundant proteins from urine through 
precipitation prior to the separation of urine proteins by electrophoresis is essential. 
 
Another disadvantage of urine is that there are wide variations in protein 
concentration owing to fluid intake in individuals (Theodorescu and Mischak, 2007). 
Theodorescu and Mischak further reported on the inconsistency of pH in urine, which 
may alter the activity of proteases. The latter factor plays a crucial role in polypeptide 
digestion in preparation for mass spectrometry as the alteration of protease activity 
may lead to variations in the composition of peptide fragments.  
 
As diabetes continues to be an important clinical problem, proteinuria has been 
classified as an emerging major cause of morbidity in humans (Candiano et al., 2008). 
Furthermore it is considered a major factor in renal failure and renal fibrosis and can 
also potentially trigger kidney inflammation.  
 
Another proteomics study assisted in the identification of urinary protein markers in 
the prediction of diabetic kidney disorders (Jain et al., 2005). The study revealed four 
main proteins involved in diabetic kidney disorders.  The proteins were identified as 
Alpha-1 microglobulin which is related to the severity and control of type II diabetes; 
Alpha-1 acid glycoprotein which is a marker for inflammation and also predicts 
mortality; Zinc alpha-2 glycoprotein (ZAG) which is expressed in the liver, kidney, 
breast, prostrate, pancreas and various tumours. It is suggested that ZAG is a possible 
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candidate gene for regulation of body weight. The last protein identified was albumin, 
which is an early predictor of diabetes, indicating the first signs of the deteriorating 
kidney function (Jain et al., 2005; Savage et al., 1996). In addition, urinary protein 
changes in type 2 diabetic patients have been evaluated where transthyretin, a low 
molecular weight protein, was found to be abundant in type 2 diabetic nephropathy 
patients (Bellei et al., 2008). 
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1.5.3 Aims and objectives of the study 
 
Aims: 
The study was aimed at using proteomics to identify the differential expression of 
urinary proteins in lean and obese rats. Also to determine the utility of urine as an 
alternative source to blood in the diagnosis of prediabetes as urine can be obtained 
non-invasively. 
 
Objectives: 
The specific objectives of the study were to: 
• Collect urine from lean and obese Wistar rats and establish a method for the 
enrichment of low abundance and low molecular weight proteins. 
• To generate 2D urine proteome profile maps of the lean and obese Wistar rats. 
• To visualize and to identify differentially expressed urinary proteins between 
the lean and obese Wistar rats through mass spectrometry analysis. 
 
1.5.4 Hypothesis 
 
It is hypothesised that the differentially expressed proteins involved during obesity 
development will act as potential diagnostic markers and therapeutic targets. 
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CHAPTER 2: MATERIALS AND METHODS 
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2.1 Materials and suppliers 
 
Materials (Chemical, reagents) Suppliers (company 
details in Appendix) 
 
Acetone       Merck 
Acetonitrile        Merck 
Acrylamide (40 % 37.5:1 acylamide:bisacrylamide)  Bio-Rad  
Agarose       Whitehead Scientific  
Ampholytes       Bio-Rad 
APS (Ammonium persulfate)     Sigma 
Bio Rad dye reagent      Bio-Rad 
Bromophenol blue sodium salt    Sigma – Aldrich 
BSA (Bovine Serum Albumin)    Seravac 
Bovine insulin       Applied Biosystems  
CHAPS       Sigma  
CHOW diet       Epol 
Coomassie Brilliant Blue R-250     Sigma  
DTT        Fermentas  
Glacial Acetic acid      Merck 
Glycerol       Merck 
Glycine       Bio-Rad 
Hydrochloric acid (HCl)     Merck  
Iodoacetamide       Bio-Rad  
IPG Strips       Bio-Rad 
Ketostix Reagent Strips     Bayer 
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PlusOne Drystrip cover fluid     Amersham Biosciences 
Propan-2-ol       Merck 
SDS (Sodium dodecyl sulfate)    Bio-Rad 
TCA        Merck  
TEMED       Bio-Rad 
Tris        Merck 
Thiourea       Sigma  
Urea        Sigma 
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2.2 Buffers and solutions 
 
1 % Agarose    1 % agarose dissolved in 1 X SDS buffer 
 
2 X Sample buffer 0.5 M Tris pH 6.8, 20 % glycerol, 10 % SDS and 
0.1 % (w/v) bromophenol blue 
 
5 % Stacking gel 0.063 M Tris pH 6.8, 5 % acrylamide, 0.1 % SDS,  
0.1 % APS and 0.1 % TEMED 
 
10 % APS 0.1 g ammonium persulfate dissolved in 1 ml 
distilled water 
 
10 % SDS    10 % SDS dissolved in distilled water 
 
10 X SDS buffer 25 mM Tris, 192 mM glycine and 0.1 % SDS 
dissolved in distilled water. Adjusted to pH 7.5 
 
1 X SDS buffer 100 ml of mixed 10 X SDS buffer with 900 ml of 
distilled water 
 
12 % Separating gel 0.375 M Tris pH 8.8, 12 % acrylamide, 0.1 % SDS,  
0.1 % APS and 0.1 % TEMED 
 
50 % DTT 0.05 % of DTT and a tinge of bromophenol blue 
dissolved in lysis buffer 
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Bio-Rad dye reagent   1 part Bio-Rad dye reagent with 4 parts distilled 
Water 
 
Coomassie I Staining Solution 10 % glacial acetic acid, 0.025 % (w/v) Coomassie 
Brilliant blue R-250 and 25 % propan-2-ol 
dissolved in distilled water 
 
Coomassie II Staining Solution 10 % glacial acetic acid, 0.003125 % (w/v) 
Coomassie Brilliant blue R-250 and 10 % propan-2-
ol dissolved in distilled water 
 
Coomassie III Staining Solution 10 % glacial acetic acid and 0.003125 % (w/v) 
Coomassie Brilliant blue R-250 dissolved in 
distilled water 
 
Destaining Solution 10 % glacial acetic acid and 1 % glycerol dissolved 
in distilled water 
 
Equilibration base buffer 6 M Urea, 2 % SDS, 0.05 M Tris-HCl and 20 % 
glycerol dissolved in distilled water, pH 8.8 
 
Equilibration buffer 1 6 M Urea, 2 % SDS, 0.05 M Tris-HCl, 20 % 
glycerol and 2 % DTT dissolved in distilled water, 
pH 8.8 
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Equilibration buffer 2 6 M Urea, 2 % SDS, 0.05 M Tris-HCl, 20 % 
glycerol and 2.5 % iodoacetamide dissolved in 
distilled water, pH 8.8 
 
High fat diet 5 480 g CHOW (rat pellets), 3 200 g lard, 160 ml 
oil, 640 g sugar, 80 g vitamin mix, 40 g minerals, 
20 g ascorbic acid and 35 ml vitamin D 
 
Solubilization buffer 7 M urea, 2 M thiourea, 4 % CHAPS and a tinge of 
bromophenol blue dissolved in water 
 
Tris pH 6.8 0.5 M Tris dissolved in distilled water. Adjusted pH 
with HCl 
 
Tris pH 8.8 1.5 M Tris dissolved in distilled water. Adjusted pH 
with HCl 
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2.3 Animal models 
 
For the study, 20 male Wistar rats were used as animal models. The animals were 
maintained at the MRC Primate and treated according to the rules of the MRC Ethics 
Committee. The rats were weaned on a balanced standard CHOW diet for four weeks. At 
four weeks, the rats were equally divided into two groups (10 rats per group). One group 
was fed CHOW diet and the other was fed a HF ad libitum. The two groups were kept on 
their respective diets for 18 weeks. The body weights were recorded before urine 
collection. 
 
2.4 Urine collection 
 
Urine was collected from all rats. Rats were placed in metabolic chambersand 
acclimated for 24 hours. Ketostix were used to measure the ketone levels of each 
urine sample.  To protect the urine from proteases 1 mM PMSF was added to the 
urine samples. Urine samples were then centrifuged and stored in 2 ml aliquots at -20 
˚C until required for further use. 
 
2.5 Urine (sample) preparation 
 
2.5.1 Protein determination 
 
This step was taken in order to examine the presence of proteins in urine. Each 2 ml 
untreated urine sample was thawed and briefly spun. Urinary proteins were resolved 
on 12 % SDS PAGE gel according to Laemmli’s method (Laemmli UK, 1970), which 
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utilizes a stacking gel to concentrate the proteins into a line before they enter the 
separating gel, which then separates them according to their molecular weight. Ten #l 
from each urine sample was mixed with equal volume of 2 X sample buffer and 
boiled in the heating block (Block Heater, Stuart Scientifica) at 95 °C for 5 minutes. 
The samples were cooled at room temperature then pulse spun in the microcentifuge 
(Eppendorf Microcentrifuge Model 5417, Sigma-Aldrich). The samples were then 
loaded on the gels. Electrophoresis was carried out at 100 V for 90 minutes.  
 
2.5.2 SDS PAGE Staining 
 
Following electrophoresis, the gels were stained using the three-step coomassie 
staining. The gels were first placed in the coomassie I stain solution then heated in a 
microwave for 1 minute at 900 watt and incubated overnight at room temperatue with 
agitation. The stain was decanted, replaced with coomassie II stain solution and 
heated in a microwave for 1 minute at 900 watt. The gels were incubated with the 
stain for 30 minutes with agitation. Following staining with coomassie II staining 
solution, the stain was decanted, replaced with coomassie III staining solution then 
heated in a microwave for about 1 minute at 900 watt. The gels were incubated with 
the stain for 30 minutes with agitation. The stain was decanted and the gels were 
destained with the destaining solution until the desired protein bands or spots were 
achieved. The images were captured with a digital camera (Olympus Optical). 
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2.5.3 Protein precipitation 
 
After confirming the presence of proteins in urine, the urinary proteins were 
precipitated using three different precipitation methods namely; acetone, acetonitrile 
and TCA-acetone.  The acetone, acetonitrile and TCA-acetone were pre-chilled at -20 
˚C.  
 
2.5.3.1 Acetone precipitation 
 
Precipitation of urinary proteins with acetone was carried out as described by Khan 
and Packer (Khan and Packer, 2006). 
 
To prepare the samples for acetone precipitation, a 1:5 urine-to-acetone ratio was used 
to precipitate urine proteins (Khan and Packer, 2006). The urinary proteins were 
precipitated overnight at -20 ˚C.  Following overnight precipitation, the samples were 
centrifuged at 14 000 rpm for 15 minutes at 4 ˚C. The supernatants were stored at -20 
˚C for later use and the pellets were resuspended in 200 #l of solubilization buffer and 
stored at -20 ˚C for later use.  
 
2.5.3.2 Acetonitrile precipitation 
 
Precipitation of urinary proteins with acetonitrile was carried out as described by 
Khan and Packer (Khan and Packer, 2006).   
 
A 1:5 urine-to-acetonitrile ratio was used to precipitate urinary proteins with 
acetonitrile (Khan and Packer, 2006). The urinary proteins were precipitated 
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overnight at -20 ˚C. Following overnight precipitation, the samples were centrifuged 
at 14 000 rpm for 15 minutes at 4 ˚C. The supernatants, middle supernatants and 
upper supernatants were stored at -20 ˚C for later use and the pellets were 
resuspended in 200 #l solubilization buffer and stored at -20 ˚C for later use. 
 
2.5.3.3 TCA-acetone precipitation 
 
Precipitation of urinary proteins with TCA-acetone was carried out as described by 
Chen and coworkers (Chen et al., 2005). 
 
Urinary proteins were also precipitated using the TCA-acetone precipitation method 
(Chen et al., 2005). To prepare the samples for TCA-acetone precipitation, 100 #l of 
the urine sample was added to 100 #l of distilled water. To the mixture, 4 volumes of 
ice-cold 10 % TCA-acetone (v/v) was added and immediately mixed by gentle 
vortexing (Vortex, VELP Scientifica) for 10 minutes. The samples were incubated at -
20 ˚C for 90 minutes. Following incubation, the samples were centrifuged at 16 000  x 
g (12 274 rpm) for 15 minutes at 4 ˚C. The supernatants were carefully removed and 
transferred into new tubes and labeled accordingly. To wash the pellets, 1 ml of ice-
cold acetone was added to the pellet and incubated on ice for 15 minutes, followed by 
centrifugation at 16 000 x g (12 274 rpm) for 15 minutes at 4 ˚C. The supernatants 
were removed and mixed with the first supernatants. The pellets were briefly air-dried 
to remove excess acetone. The tubes were immediately capped. The pellets were then 
resuspended in 100 #l solubilization buffer and stored at -20 ˚C for later use.  
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To the TCA-acetone containing supernatants, 1 ml of ice-cold acetone was added. 
The tubes were then incubated on ice for 15 minutes, followed by centrifugation at 16 
000 x g (12 274 rpm) for 15 minutes at 4 ˚C. The supernatants were removed and 
discarded. The pellets were briefly air-dried, to remove excess acetone. The tubes 
were immediately capped. The pellets were then resuspended in 100 #l of 
solubilization buffer and stored at -20 ˚C for later use.  
 
2.6 One dimensional (1D) SDS-PAGE Analysis 
 
From the acetone pellet, the acetone supernatant, the acetonitrile pellet, acetonitrile 
upper supernatant, acetonitrile middle supernatant, TCA-acetone supernatant and 
TCA-acetone pellet, 10 µl respectively was mixed with equal volume of 2 X sample 
buffer and boiled in the Block Heater (Stuart Scientifica) at 95 °C for 5 minutes.  
 
Once the proteins were denatured, the samples were cooled to room temperature, 
pulse spun in the microcentifuge, then loaded on the gels by first stacking on the 5 % 
gels and resolving the proteins on the 12 % gels. The gels were assembled using the 
Mini-Protean III
® 
cell (Bio-Rad). The gels were run at 100 V for 90 minutes. The gels 
were stained as described in section 2.5.2. The image was captured with a digital 
camera (Olympus Optical). 
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2.7 Protein quantification 
 
2.7.1 Bradford protein assay 
 
The acetone pellets were thawed in preparation for the quantification of proteins. The 
protein concentrations were determined using the Bio-Rad assay. Protein 
quantification was done in duplicates. Bovine Serum Albumin (BSA) was used as a 
standard. The standard BSA concentrations were 25 µg/ml, 125 µg/ml, 250 µg/ml, 
500 µg/ml, 750 µg/ml and 1000 µg/ml. In each cuvette, 25 µl of the different 
concentrations was added to 1 ml of the BIO RAD dye reagent. 
 
From the respective acetone precipitated urine samples, 1:50 dilutions were prepared 
following the manufacturer’s directions. In each cuvette, 25 µl from the respective 
1:50 dilutions was mixed with 1 ml of the Bio-Rad dye working solution and 
incubated at room temperature for 30 minutes. Absorbance was read at the 
wavelength of 595 nm. 
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2.8 Two dimension (2D) SDS page analysis 
2.8.1 Sample solubilization 
 
100 µg of the acetone precipitated HF and CHOW urine samples were added to 1.25 
µl of ampholytes, 2 µl of 50 % DTT and solubilization buffer to the final volume of 
125 µl. 
 
2.8.2 In-gel rehydration 
The samples prepared from respective diet groups in section 2.7.1 were loaded in the 
grooves of the re-swelling tray (Amersham Biosciences). The gel sides of the 7 cm 
long IPG strips pH 4-7 (Bio-Rad) were immersed in the prepared samples in the re-
swelling tray and the IPG strips were covered with mineral oil (Amersham 
Biosciences). The respective IPG strips were re-hydrated overnight at room 
temperature.  
 
2.8.3 Isoelectric focusing (IEF) 
Following the overnight re-hydration of IPG strips, the strips were loaded on the 
Ettan
TM
IPGphorII
TM 
IEF machine (Amersham Biosciences), aligned and overlaid with 
mineral oil. The IEF machine was programmed for a three-step long run. For the first 
step, 250 V were applied for 10 minutes. For the second step, 4 000 V were applied 
for an hour. For the final step, 4 000 V were applied until 12 000 V-hours were 
reached. The IEF was carried out at 20 ˚C. 
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2.8.4 Equilibration of the strips 
Equilibration buffers 1 and 2 were prepared fresh by adding 2 % (w/v) DTT (buffer 1) 
and 2.5 %  (w/v) iodoacetamide (buffer 2) to equilibration base buffer respectively to 
make the final volume of 5 ml. Buffer 1 containing DTT reduces disulfide bonds and 
maintains monothiols in the reduced state. Buffer 2 contains iodoacetamide which 
covalently binds cysteines so that the protein cannot form disulphide bonds. 
 
Following the IEF, the strips were rinsed in water and placed in each channel of the 
rehydration/equilibration tray. Each channel was filled with 2.5ml of equilibration 
buffer 1 and incubated with gentle agitation for 20 minutes. After 20 minutes, the 
equilibration buffer 1 was decanted and each channel was refilled with 2.5 ml of 
equilibration buffer 2. The strips were then incubated with gentle agitation for 20 
minutes. The strips were rinsed with 1 X SDS buffer in preparation for the second 
dimension. 
 
2.8.5 Second dimension 
Following equilibration, the strips were placed on top of 15 % SDS PAGE gels. The 
gels were assembled using the Mini-Protean III
® 
cell (Bio-Rad).   To secure the strips, 
1 % low melting agarose gel was overlaid on top of the strips. The gels were run at 
100 V for 90 minutes. The gels were then stained using the three-step coomassie stain 
as described in section 2.5.2. The images were captured with a digital camera 
(Olympus Optical). 
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2.9 In-gel digestion 
All the spots with high intensity were excised manually and transferred into sterile 
microcentrifuge tubes. The gel pieces were washed twice with 50 mM ammonium 
bicarbonate for 5 minutes and a third time for 30 minutes with occasional vortexing. 
The gel pieces were then destained twice with 50 % (v/v) 50 mM ammonium 
bicarbonate and 50 % (v/v) acetonitrile for 30 minutes with occasional vortexing. The 
gel pieces were dehydrated with 100 µl of 100 % (v/v) acetonitrile for 5 minutes, and 
then completely desiccated under vacuum using a Speed Vac SC100 (ThermoSavant). 
Proteins were in-gel digested with approximately 120 ng sequencing grade modified 
trypsin dissolved in 25 mM ammonium bicarbonate for 6 hours at 37 °C. The protein 
digestion was stopped by adding 50 µl of 1 % (v/v) trifluoroacetic acid (TFA) and 
incubating 2-4 hours at room temperature before storage at 4 °C until further analysis. 
 
2.10  Protein identification with MALDI-TOF-MS 
 
Protein identification was carried out by Dr. Ludivine Thomas from the Proteomics 
Research Group (PRG) at the University of the Western Cape. 
 
Respective analytes consisting of digested proteins (1 µl) were mixed separately with 
the 1 µl of !-cyna-hydroxy-cinnamic (CHCA) matrix and spotted onto a MALDI 
target plate for analysis by MALDI-TOF mass spectrometry using a Voyager DE Pro 
Biospectrometry workstation (Applied Biosystems) to generate a peptide mass 
fingerprint (PMF). The MALDI-TOF was operated in the positive ion delayed 
extraction reflector mode for highest resolution and mass accuracy. Peptides were 
ionized with a 337 nm laser and spectra were acquired at 20 kV acceleration potential 
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with optimized parameters. Close external calibration was employed using the 
Sequazyme calibration
TM
 mixture II containing angiotensin I, ACTH (1-17 clip), 
ACTH (18-39 clip) and bovine insulin. This calibration method typically provided 
mass accuracy of 100 to 200 ppm across the mass range 900 to 5,000 Da. Peptide 
spectra of accumulated 1,200 shots each were automatically processed for baseline 
correction, noise removal, and peak deisotoping. Threshold was manually adjusted 
between 2 and 8 % base peak intensity.  
 
All searches were performed against the National Center for Biotechnology 
Information (NCBI) and Mass Spectrometry DataBase (MSDB) peptide mass 
databases using MASCOT (http://www.matrixscience.com/search_form_select.html).  
Candidate identifications with the highest Molecular weight search (MOWSE) scores 
were automatically considered as positive assignments. If more than one protein 
satisfied mentioned threshold criteria, the entry with the highest MOWSE score was 
assigned. 
 
2.11 Determination of the secondary structure 
Protein sequence of Transducin (beta)-like 3 was threaded through the PDB using 
GenTHREADER (Jones, 1999) and PSIPRED (McGuffin et al., 2000) for the 
prediction of the secondary structure. Subsequently a model was built using swiss-
modeller. The accuracy of the model was assessed using RAMPAGE (Lovell et al., 
2003).  
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CHAPTER 3:  RESULTS  
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3.1 ANIMAL STUDIES 
3.1.1 Body weights 
 
The animals (male rats) were fed a high fat in order to induce obesity. The body 
weights of the rats in the HF group steadily increased over a period of 18 weeks. The 
rats fed CHOW were labelled lean while the rats fed HF were obese based on the 
increase in body weight compared to lean rats. Averages of the final body weights 
from the two groups are illustrated in figure 4.1. The CHOW group had mean body 
weight of 466.54 ± 4.16 g while the HF group had a mean of 647.54 ± 7.83 g.  
 
 
Figure 3. 1 Average final body weights of CHOW and HF fed rats at 18 
weeks. 
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3.1.2 Ketone body levels 
 
Ketone bodies are produced in the blood when fat, instead of glucose, is broken down 
and used for energy source.  The Ketostix Reagent Strip results are expressed as 
negative, trace, +, + +, and + + + ("Package Insert, Bayer Ketostix Reagent Strips, 
Bayer Corp., Diagnostics Division, Elkhart, Indiana. ,"). Figure 3.2 demonstrates 
average ketone body levels in CHOW and HF fed rats. The average ketone body 
levels in CHOW and HF fed rats were 0.5 ± 0 mmol/L and 1.5 ± 0 mmol/L 
respectively. A trace of ketone bodies present in the urine of CHOW fed rats is 
equivalent to 0.5 mmol/L. Ketone bodies of 1.5 mmol/L are equivalent to a +. This 
indicates the formation of ketone bodies, which should be a caution for diabetes. 
Individuals with urinary ketone bodies above 1.5 mmol/L, which are + +, and + + +, 
are classified as diabetic. 
 
Figure 3. 2 Average ketone body levels in CHOW and HF fed rats. 
The Ketostix Reagent Strips were immersed in CHOW and HF urine respectively and 
the results were read after 40 seconds. 
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3.2 OPTIMIZATION OF SAMPLE PREPARATION PROTOCOLS 
AND SDS PAGES 
 
3.2.1 Urine protein determination 
To determine whether proteins were present in the urine samples, 10 µl of urine from 
the lean (CHOW fed) and obese (HF fed) rats was separated on a 12 % SDS PAGE. 
Figure 3.3 illustrates untreated urine protein profiles. Three bands were visually 
identified. The 1D PAGE showed that low molecular weight (LMW) proteins 
indicated as ‘b’ were highly expressed in both groups. These proteins were however 
highly expressed in obese rats than lean rats. 
 
 
Figure 3. 3  1D protein profiles of untreated CHOW and HF urine. 
Untreated urine from CHOW fed (A), and HF fed (B) separated on a 12 % SDS 
PAGE with protein bands a, b and c indicating highly expressed proteins. 
 
 
 
 
 
b 
c 
a 
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3.3 PROTEIN PRECIPITATION 
 
To remove the salt and to enhance LMW proteins, urinary proteins were precipitated 
using three different methods, TCA-acetone, acetone and acetonitrile and resolved on 
a 12 % SDS PAGE. Figure 3.4 shows the protein patterns obtained using different 
precipitation methods. Using the TCA-acetone method, one band at approximately 17 
kDa was observed from the pellet. Faint protein bands were seen in the supernatant. 
Both the supernatant and the pellet from the TCA-acetone method showed loss or 
removal of the proteins from the samples.  
 
Using the acetone method, protein bands from the pellet were intense and resembled a 
similar protein pattern to the untreated urine protein expression pattern. Therefore 
urinary proteins were enhanced in the pellet when using the acetone method whilst 
supernatant showed fewer proteins compared to the untreated urine. With the 
acetronitrile method, no proteins were recovered in the supernatant. The middle 
supernatant showed the removal of the high molecular weight proteins, which were 
seen around 55 kDa. However, proteins between 55 kDa and 17 kDa had disappeared 
and were not recovered in the pellet. Proteins disappeared when using the acetonitrile 
method. Therefore the acetone precipitation was a desired method as it showed better 
protein recovery and also enhanced LMW proteins. Urinary proteins were thus 
precipitated using the acetone precipitation protocol and the pellets were kept for 
further analysis. Supernatants were discarded, as LMW proteins were not enhanced. 
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Figure 3. 4 A 12 % SDS PAGE of protein profiles obtained from different 
precipitation methods. 
Lane 1 = molecular weight marker; lane 2 = untreated HF fed rat urine; lane 3 = 
TCA-Acetone supernatant; lane 4 = TCA-Acetone pellet; lane 5 = acetone 
supernatant; lane 6 = acetone pellet; lane 7 = acetonitrile supernatant, lane 8 = 
acetonitrile middle supernatant; and lane 9 = acetonitrile pellet. Where M = molecular 
weight marker; U = untreated HF urine; S = supernatant; MS = middle supernatant; P 
= pellet. 
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3.3.1 Protein Quantification 
 
Following acetone precipitation, the pellet proteins were quantified using the Bio-Rad 
protocol. Urine protein concentrations varied between the CHOW and the HF group 
with average concentrations of 0.91 µg/µl and 0.78 µg/µl respectively. Once the 
protein concentrations were determined, 20 µg of acetone precipitated proteins from 
CHOW and HF were separated on a 12 % SDS PAGE to determine the 1D urinary 
protein profiles as illustrated in figure 3.5. The PAGE showed distinct differences 
between the two groups. CHOW fed rats had 3 proteins at approximately 50 kDa 
whereas one band was observed from the HF fed rats (indicated as ‘a’). Three protein 
bands were observed below 26 kDa in both groups. This is indicated as ‘b’. Although 
these three proteins were observed in both groups, their intensity was higher in the HF 
group. The protein profile showed that LMW proteins were abundant in both the 
CHOW and HF fed rats. 
 
Figure 3. 5 1D SDS PAGE urine protein profiles of the pellets from HF 
and CHOW fed rats following acetone precipitation. 
Lane 1 shows the molecular weight marker. Lanes 2, 4, 6, 8 and 10 show urine proteins 
from CHOW fed rats and lanes 3, 5, 7 and 9 show urine proteins from HF fed rats. 
a 
b 
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3.3.2 2D SDS-PAGE 
 
Subsequent to the determination of the 1D SDS PAGE urine profiles, urinary proteins 
from the CHOW fed and High Fat (HF) fed rats were analysed on 2D SDS PAGE 
gels to determine their respective protein profiles. Prior to the development of 2D 
urine profiles certain parameters, such as IPG strips and the focusing conditions were 
optimised. Different pH range strips namely, pH 3-10 and pH 4-7 were used.  
 
Initially broad range, pH 3-10, IPG strips were used to separate the proteins. 100 µg 
of urine proteins from the five rats per group were analysed. The proteins were 
initially focused at 250 V for 10 minutes, then at 4 000 V for an hour and finally at 
4000 V until 10 000 V hours were reached. The strips were then equilibrated for 10 
minutes and the proteins resolved on a 12 % SDS PAGE.  The resulting gel was 
stained as in section 2.5.2. Upon viewing the gel, the gel was of poor resolution 
showing clustered protein spots with vertical streaks. The vertical streaks might have 
been as a result of incomplete reduction or alkylation. Though the gel was of poor 
resolution, proteins of interest appeared in the narrow range. The protein spots of 
interest were also observed to be of molecular weight below 30 kDa.  
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To improve the gel quality for detailed analysis, 7 cm long IPG strips pH 4-7 were 
used to separate the proteins. To optimize the running conditions, the duration of the 
third step in the focusing of proteins was increased from 10 000 V-hrs to 12 000 V-
hrs at a current of 4 000 V at a constant temperature of 20 °C. To decrease the vertical 
streaks, the equilibration time was increased from 10 minutes in each buffer to 20 
minutes in the respective equilibration buffers.  
 
The resolving gel percentage was increased from 12 % to 15 % SDS PAGE to 
improve the resolution of LMW proteins. Five SDS PAGE gels in figure 3.6 show the 
resulting protein profiles. Similar protein expression profiles were seen between the 
rats in the respective groups. However only two gels, one from each diet group, were 
chosen to represent the protein profiles from each diet group. The proteomic profiles 
showed LMW proteins ranging between 10 kDa and 30 kDa. The 2D SDS PAGE gels 
were analysed visually.  
 
From the CHOW 2D SDS PAGE protein profile, 20 spots were identified. The spots 
were labelled with C, denoting CHOW followed by the spot number. From the HF 2D 
SDS PAGE protein profile, 21 spots were identified. The spots were labelled with HF, 
denoting High Fat followed by the spot number. The CHOW and HF protein profiles 
are illustrated in figure 3.7 and 3.8, respectively. 
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Figure 3. 6 2D SDS PAGE urine protein profiles of HF and CHOW fed rats. 
Urine proteins of CHOW and HF fed rats were first separated on charge according to their isoelectric point and then separated according to their 
mass on 15 % SDS PAGE gels. The CHOW 2D profiles are shown in A and the HF 2D profiles are shown in B. 
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Figure 3. 7 A 15 % 2D SDS-PAGE urinary protein profile of CHOW fed rats. 
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Figure 3. 8 A 15 % 2D SDS-PAGE urinary protein profile of HF fed rats.
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The CHOW and HF protein profiles had similar protein expression pattern. However, 
the HF protein profile had one protein, HF2, which was not expressed by the CHOW 
fed rats. When comparing the CHOW and HF protein profiles it was noticed that there 
were increased urinary proteins in the HF group than in the CHOW group. There is 
however a noticeable decrease in some of the urinary proteins excreted from the HF 
group when compared to the CHOW group. The increase and decrease in CHOW and 
HF urinary proteins were measured visually either by the increase, decrease or both 
the increase and decrease in protein spots intensity and size. When comparing the two 
groups, there were 3 increased and 4 decreased urinary proteins from the HF protein 
profile when compared to the CHOW protein profile. Magnified increased and 
decreased urinary spots from the CHOW and HF 2D protein profiles are provided in 
figure 3.9.  
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Figure 3. 9 Differentially expressed CHOW and HF urinary proteins 
A) Magnified decreased HF urinary proteins in comparison to CHOW urinary 
proteins. B) Magnified increased HF urinary proteins in comparison to CHOW 
urinary proteins. 
 
 
 
 
A) 
B) 
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3.4 PROTEIN IDENTIFICATION 
Following the successful separation of the proteins, the labelled 41 protein spots (20 
CHOW and 21 HF) were excised from the 2D gels and digested with trypsin. This 
was done in order to generate peptides. The respective analytes were then mixed with 
the matrix and a laser was applied to the source plate. The matrix absorbed the energy 
from the laser and transferred it to the analytes. The ions were then analysed 
according to their mass/charge ratio. A mass list was then created from which peaks 
were matched on the database to identify the protein. 
 
3.4.1 Mass spectrometry analysis 
Significant proteins were identified according to the probability-based Mowse score 
and were matched on the Mascot database. The protein Mowse score was calculated 
as -10logP, where P is the absolute probability of matching a number of peaks by 
random chance at a significance threshold of p<0.05. Tables 3.1 and 3.2 illustrate the 
summary of the identified proteins from CHOW and HF respectively using the 
MALDI-TOF-MS. 
 
The Mascot database showed that spots CH1 and HF1 have similar ion spectra 
although there was no positive identification on the protein. The spectra are shown in 
figure 3.10. Three similar peaks were identified from the spectra at approximately 
2211, 1297 and 2809. This suggests that there is possibility of CH1 and HF1 being the 
same protein. Spots C2, C3 and HF3 had similar ion spectra, shown in figures 3.11 
and 3.12, and were identified as Serotonin 5-HT2C also referred to as 5-
hydroxytryptamine (serotonin) receptor 2c.  
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Table 3. 1. The identified proteins from the CHOW fed rats analysed by MALDI-TOF MS based on the MASCOT database 
Spot     Protein Name                               Accession          Estimated MW  MW        pI         MOWSE   
No.                                                              No.                    (kDa)    (kDa)                  Score 
 
1 No positive identification     15 
2 Serotonin 5-HT2c   Q62842  14    33.63   9.52   59   
3 Serotonin 5-HT2c   Q62842  14    33.63   9.52    62 
4 No positive identification     14 
5 No positive identification     14 
6 No positive identification     18 
7 No positive identification     17 
8 Alpha-2u Globulin precursor   S05440  17    20.33   4.86   86 
9 Alpha-2u Globulin PGCL4             gi| 76880469  17    20.33  4.86   82 
10 Alpha-2u Globulin PGCL4  gi| 76880469  17    20.33   4.86   80 
11 No positive identification     17 
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Spot     Protein Name                               Accession          Estimated MW  MW          pI         MOWSE  
No.                                                              No.                    (kDa)    (kDa)                    Score 
 
12 Alpha-2u Globulin, Chain A  2A2GA  17    18.30   5.30   100 
13 Alpha-2u Globulin precursor   gi| 204261  17    20.16   5.43   79 
14 No spectrum found      17 
15 Alpha-2u Globulin precursor   gi| 204261  17    20.16   5.43   82 
16 Hypothetical protein LOC683313 gi| 155369696  17    59.21   8.06   80 
17 No spectrum found      17 
18 Alpha-2u Globulin precursor  gi| 204261  17    20.16   5.43  111 
19 Alpha-2u Globulin precursor  gi| 204261  17    20.16   5.43  107 
20 Alpha-2u Globulin precursor  gi| 204261  17    20.16   5.43   94 
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Table 3. 2. The identified proteins from the HF fed rats analysed by MALDI-TOF MS based on the MASCOT database 
Spot     Protein Name                               Accession         Estimated MW   MW       pI         MOWSE  
No.                                                              No.                    (kDa)    (kDa)                  Score 
 
1 No positive identification      15 
2 Transducin (Beta)-like 3  Q5U2W5_RAT  14   88.31   6.26   60 
3 Serotonin 5-HT2c   Q62842   14   33.63   9.52    61 
4 No positive identification      14 
5 No positive identification      14 
6 No positive identification      14 
7 No positive identification      18 
8 No positive identification       17    
9 Alpha-2u Globulin PGCL4             gi| 76880469   17   20.33   4.86   73 
10 Alpha-2u Globulin PGCL4  gi| 76880469   17   20.33   4.86   108 
11 No positive identification      17 
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Spot     Protein Name                               Accession   Estimated MW  MW      pI         MOWSE  
No.                                                              No.                    (kDa)    (kDa)                 Score 
 
12 No positive identification      17 
13 Alpha-2u Globulin precursor   gi| 204261   17   20.16   5.43   72 
14 Alpha-2u Globulin precursor  gi| 204261   17   20.16   5.43   168 
15 Alpha-2u Globulin precursor   gi| 204261   17   20.16   5.43   176 
16 Alpha-2u Globulin precursor  gi| 204261   17   20.16   5.43   146 
17 Alpha-2u Globulin precursor  gi| 204261   17   20.16   5.43   152 
18 Alpha-2u Globulin precursor  gi| 204261   17   20.16   5.43   76 
19 Alpha-2u Globulin precursor  gi| 204261   17   20.16   5.43   68 
20 No positive identification 
21 Alpha-2u Globulin precursor  gi| 204261   17   20.16   5.43   119 
 
 
 
 
 
  
 
Figure 3. 10 MALDI-TOF mass spectra of a trypsin digested CH1 and HF1 
protein spots. 
Spots C1 and HF1 were cut from the gel and digested with trypsin. The eluates were mixed 
1:1 with !-CHCA matrix solution, 1 "l was spotted onto a MALDI plate and allowed to air 
dry before MALDI-TOF MS analysis.  
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Figure 3. 11 Mass spectrum of C2 trypsin digested protein spot with the 
matched protein sequence. 
Spot C2 was cut from the gel and digested with trypsin. The eluate were mixed 1:1 with !-
CHCA matrix solution, 1 "l was spotted onto a MALDI plate and allowed to air dry before 
MALDI-TOF MS analysis. Sequence was identified using the Mascot search that showed 
the matched peptides in red. 
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Figure 3. 12 Mass spectrum of C3 and HF3 trypsin digested protein spot 
with their matched Serotonin 5-HT2C protein sequence. 
Spots C3 and HF3 were cut from the gel and digested with trypsin. The spectra were 
generated using the MALDI-TOF MS. Sequence was identified as Serotonin 5-HT2C 
using the Mascot search that showed the matched peptides in red with a sequence 
coverage of 25 % for spot C13 and 22 % for protein spot HF3. 
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Protein spots C4 and HF5 had similar ion spectra with no positive identification on the 
protein. The spectra are shown in figure 3.13. Three similar peaks were identified from 
the spectra at approximately 2125, 2146 and 2190.  
 
 
Figure 3. 13 Mass spectra of the digested C4 and HF5 protein spots. 
Spots C4 and HF5 were cut from the gel and digested with trypsin. The spectra were 
generated using the MALDI-TOF MS.  
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Figure 3. 14 Similar CHOW mass spectra of C6, C7 and C11 trpysin 
digested protein spots. 
Spots C6, C7 and C11 were cut from the gel and digested with trypsin. The eluates were 
mixed 1:1 with !-CHCA matrix solution, 1 "l was spotted onto a MALDI plate and allowed 
to air dry before MALDI-TOF MS analysis.  
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Figure 3. 15 Similar HF mass spectra of HF7, HF8 and HF12 trpysin 
digested protein spots 
Spots HF7, HF8 and HF12 were cut from the gel and digested with trypsin. The spectra 
were generated using the MALDI-TOF MS.  
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Protein spots C6, C7, C11, HF7, HF8 and HF12 also had similar ion spectra with no 
positive protein identity. The spectra are shown in figures 3.14 and 3.15. Three 
similar peaks were identified from the spectra at approximately 1613, 1630 and 2097. 
The spectra show that the peptides have similar masses but differ in abundance. The 
peptides are probable isoforms of the non-identified protein.  
 
Protein spot C12 was identified as alpha-2u globulin, chain A. is also known as the 
Major Urinary Protein (MUP). Alpha-2u globulins are encoded by a highly 
homologous multigene family. Moreover, protein spots C9, C10, HF9 and HF10 were 
identified as alpha-2u globulin isoform, alpha-2u globulin PGCL4. Protein spots C8, 
C13, C15, C18, C19, C20, HF13, HF14, HF15, HF16, HF17, HF18, HF19 and HF21 
were identified as another alpha-2u globulin isoform named alpha-2u globulin 
precursor.  The spectra of the latter protein spots have similar masses but differ in 
abundance (figures 3.16 – 3.24). Although no identity was found for the HF20 protein 
spot, it possible that it is also an alpha-2u globulin precursor because its spectrum is 
similar to that of protein spots C8, C13, C15, C18, C19, C20, HF13, HF14, HF15, 
HF16, HF17, HF18, HF19 and HF21. It is possible that it could not be identified 
because of the low abundance of peptides. 
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Figure 3. 16 Mass spectrum of the trypsin digested C8 with the alpha-2u 
globulin precursor sequence.  
The spectrum was generated using the MALDI-TOF MS. From the Mascot search 32 % of 
the sequence was covered with matched peptides indicated in red. 
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Figure 3. 17 Mass spectra of the digested C13 and C15 protein spots and 
identified sequence of C15. 
Spots C13 and C15 were cut from the gel and digested with trypsin. The eluates were 
mixed 1:1 with !-CHCA matrix solution and 1 "l was spotted onto a MALDI source 
plate. MALDI-TOF MS was used in the generation of the mass spectra. The Mascot 
search showed sequence coverage of 38 % from C15 protein spot. 
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Figure 3. 6 Mass spectra of the digested C18 and C19 protein spots and 
their respective identified sequences. 
Spots C18 and C19 were cut from the gel and digested with trypsin. MALDI-TOF MS 
was used in the generation of the mass spectra. The Mascot search showed sequence 
coverage of 58 % from C18 and sequence coverage of 54 % from C19 with these 
matched peptides indicated in red. 
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Figure 3. 7 MALDI-TOF mass spectrum of the trypsin digested HF13 and 
HF 14 with their identified alpha-2u globulin precursor sequence. 
Spots HF13 and HF14 were cut from the gel and digested with trypsin. MALDI-TOF 
MS was used in the generation of the mass spectra. The Mascot search showed 
sequence coverage of 47 % from HF13 and 67 % for HF14 with matched peptides 
indicated in red. 
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Figure 3. 80 Mass spectra of the digested HF15 and HF16 protein spots 
and their respective identified sequences. 
Spots HF15 and HF16 were cut from the gel and digested with trypsin. MALDI-TOF 
MS was used in the generation of the mass spectra. The Mascot search showed 
sequence coverage of 68 % from HF15 and 57 % for HF16 with matched peptides 
indicated in red. 
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Figure 3. 21 MALDI-TOF mass spectra of the digested HF17 and HF18 
protein spots and their respective identified alpha-2u globulin precursor 
sequence. 
Spots HF15 and HF16 were cut from the gel and digested with trypsin. MALDI-TOF 
MS was used in the generation of the mass spectra. 
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Figure 3. 9 Mass spectrum of HF19 trypsin digested protein spot with the 
matched protein sequence. 
Spot HF19 was cut from the gel and digested with trypsin. The eluate were mixed 1:1 
with !-CHCA matrix solution, 1 µl was spotted onto a MALDI plate and air-dried before 
MALDI-TOF MS analysis. Sequence was identified using the Mascot search that showed 
the matched peptides in red with 50 % sequence coverage. 
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Figure 3. 23 MALDI-TOF mass spectrum of trypsin digested HF21 protein 
spot with the matched protein alpha-2u globulin precursor sequence. 
Spot HF19 was cut from the gel and digested with trypsin. MALDI-TOF MS was 
used in the generation of the mass spectra. Sequence was identified using the Mascot 
search that showed the matched peptides in red with 67 % sequence coverage. 
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Figure 3. 24 Mass spectrum of trypsin digested HF20 protein spot. 
Spots HF20 was cut from the gel and digested with trypsin. MALDI-TOF MS was 
used in the generation of the mass spectra. 
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3.4.2 Transducin (beta)-like 3 protein 
The only protein spot observed from the obese rats and not from the lean rats was 
identified as the Transducin (beta)-like 3 protein that is abbreviated as Tbl3. The 
spectrum obtained using the MALDI-TOF MS is shown in figure 3.25. The Mascot 
results showed sequence coverage of only 11 %. The matched peptides are indicated 
in bold red in figure 3.26. The calculated mass of Tbl3 is 88.24 kDa and the protein 
was observed at approximately 14 kDa. The protein appears to be truncated or to be a 
proteolytic fragment of a larger protein. 
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Figure 3. 25 MALDI-TOF mass spectrum of trypsin digested HF2 protein spot. 
Spot HF19 was cut from the gel and digested with trypsin. MALDI-TOF MS was used in the generation of the mass spectra. Sequence was 
identified using the Mascot search that showed the matched peptides in red with 67 % sequence coverage. 
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Figure 3. 26 A transducin (beta)-like 3 amino acid sequence, the matched peptides in bold red indicating 11 % sequence 
coverage. 
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3.5 PROTEIN MODELLING  
In order to gain insight of the differential protein, a model of Tbl3 was generated 
based on its homology to the WD family. A secondary structure was designed guided 
by the principles and predictions from GenTHREADER (Jones, 1999) and PSIPRED 
(McGuffin et al., 2000). PSIPRED (McGuffin et al., 2000) revealed a high prediction 
confidence secondary structure with 9-helical regions, 59 beta strands and 67 loop 
regions (shown in figure 3.27). The search for structural alignment using the Tbl3 
protein sequence against the known structures in the PDB using GenTHREADER 
(Jones, 1999) showed 2 candidates, 1pguA and 1nroA. The identified candidates are 
actin-interacting protein 1 (Aip1p) which is a WD repeat protein reported to regulate 
cofilin-mediated actin filaments depolymerization. 
 
The model was further evaluated with RAMPAGE (Lovell et al., 2003), to check for 
possible errors in the stereochemistry. A Ramachandran plot obtained from the model 
showed that 86.4 % of the residues were in the sterically favoured region where 98 % 
of the residues in the sterically favoured region were expected.  The plot is shown in 
figure 3.29. The remaining 7.6 % fell within allowed regions whereas approximately 
2 % was expected. The model showed that 6 % was in the disallowed regions, this 
might be owing to the high number of loop regions. A cartoon presentation of the 
model acquired using PyMOL v0.97 (DeLano, 2002) is shown in figure 3.28. 
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Figure 3. 27 The predicted secondary structure of Tbl3 generated using 
PSIPRED (McGuffin et al., 2000). 
The image suggests that Tbl3 is expected to contain mostly loop regions and beta 
strands. 
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Figure 3. 28 A cartoon presentation of the Tbl3 model. 
The figure was generated using PyMOL (DeLano, 2002). The image suggests that 
Tbl3 model contains mostly loop regions and beta strands. 
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Figure 3. 29 A Ramachandran plot of the Tbl3 model generated using 
RAMPAGE (Lovell et al., 2003). 
The area shaded in blue represents the allowed and favoured regions on the plot. The 
glycines have been represented by asterisks while the prolines have been represented 
by triangles. 86.4 % of the residues were predicted within the favoured region, 7.6 % 
were predicted within the allowed regions while 6 % was in the disallowed regions.  
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CHAPTER 4: DISCUSSION AND CONCLUSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 88 
    
 
The analysis of human body fluids is one of the most important approaches to the 
diagnosis of diseases or the development of therapeutic interventions in diseases. 
Sample preparation is said to be the most important in downstream steps, in obtaining 
reproducible and high-resolution gels, as this will affect the ultimate analytical results. 
However, sample preparation methods varied from one publication to another. 
Therefore it was of utmost importance to establish a method for the enrichment of low 
molecular weight proteins in urine of CHOW and HF fed rats. It is worth noting that 
urinary protein concentrations are much lower than in serum mainly because the 
glomerular filtration takes place in the kidneys (Gonza!lez-Buitrago et al., 2007; 
Theodorescu and Mischak, 2007). This explains the low molecular weight proteins 
that were observed from the gels. In comparison with other body fluids such as serum, 
albumin is still a major protein or a highly abundant protein that interferes with the 
detection of low abundant proteins and low molecular weight proteins. The study 
established an approach or method for the depletion of high abundant proteins and the 
enrichment of low molecular weight proteins through acetone precipitation of urine 
samples. 
 
From the 2D urine proteome profile between the CHOW and HF fed rats only one 
protein was different. This protein was observed on the HF proteome profile but not 
on the CHOW proteome profile. Also observed from the HF proteome profile were 
four decreased protein spot intensities and three increased protein spot intensities. 
According to Bellei and co-workers, increased excretion of urinary proteins may be 
owing to various sources such as increased glomerular filtration of plasma proteins; 
impaired tubular reabsorption of filtered proteins; and proteins that originate from 
injured glomeruli, tubules, infiltrating inflammatory cells as well as those that enter 
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the urine in the urinary tract below the kidney (Bellei et al., 2008). It is therefore 
possible that the rats fed a high fat diet may have developed an injury to the kidney as 
a result of injured glomeruli.  The mechanism behind the increase and decrease of 
protein spot intensities from the CHOW fed rats is not yet known. 
 
Despite the increase and decrease in protein spot intensities, all the identified spots 
were identified using MALDI-TOF-MS, their ion spectra were generated, the peaks 
from the mass list were then matched on the database. All searches were performed 
against the NCBI and MSDB peptide mass databases using MASCOT. From both the 
lean and obese rats, Serotonin 5-HT2C, Alpha-2u Globulin PGCL4, Alpha-2u 
Globulin precursor and the Chain A of Alpha-2u Globulin, which was only observed 
in the lean rats, were identified. 
 
Even though the proteins were identified, only a percentage of the identified protein 
sequence was recovered and their observed molecular weight was below the 
theoretical molecular weight. This suggests that the proteins might have been cleaved 
or truncated. Fliser and co-workers have also noted that the identified biomarkers 
from urine of patients with renal diseases are proteolytic fragments of larger proteins 
(Fliser et al., 2007). In addition, nephropathy and kidney disease studies have 
indicated that there are specific proteases in urine, which cleave the excreted proteins 
as a result of several glomerular diseases (Fliser et al., 2007). 
 
The Serotonin 5- HT2C receptor is one of the 14 subtypes of 5-HT serotonin receptors. 
Serotonin 5- HT2C is a biogenic hormone according to the database, that function as a 
mitogen, a hormone and neurotransmitter. The 5- HT2C receptor is a seven trans-
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membrane G-protein coupled receptor associated with the activation of a 
phosphatidylinositol-calcium second messenger system. It is also reported that altered 
patterns of RNA editing in response to drug treatment and stressful situations have 
been observed in rodent studies such those by (Zhang et al., 2009).  
 
The other identified protein, Alpha-2u globulin, is a tissue and sex-specific protein. It 
is expressed in male rats and has been shown to be highest in young male rats 
(Swenberger, 1993). In addition, Alpha-2u globulin is reported to be suppressed by 
oestrogen. It is synthesized and secreted by parenchymal cells. It is a LMW protein of 
approximately 19 kDa. It is first synthesized as a 21 kDa precursor that is then 
processed to be a mature protein (Saito et al., 2000; Unterman et al., 1981).  
 
The only protein spot observed from the obese rats and not from the lean rats was 
identified as Transducin (beta)-like 3 protein. Transducin (beta)-like 3 protein is 
abbreviated Tbl3. According to NCBI and MSDB, Tbl3 has conserved protein 
repeats. These beta-transducin repeats are also known as WD40 repeats. Tbl3 has 13 
conserved WD repeat proteins.  
 
WD40 repeats were originally identified in the beta subunit of the heterotrimeric G-
protein (G!) (van der Voon and Ploegh, 1992). The repeats are usually 4-8 repeat 
sequences. The WD40 repeat motifs are divided into two conserved elements A and B 
(Saeki et al., 2006). The A elements are said to be poorly conserved with a pair of 
glycine and histidine (GH) whilst the B elements are well conserved with a pair of 
tryptophan and aspartate (WD). The repeats are thus called WD40, as they are usually 
approximately 40 amino acid motifs terminating in a WD dipeptide. 
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The WD40 repeat proteins have been found in a number of eukaryotes. According to 
van der Voon and Ploeg, the WD40 family members include the !-subunit of guanine 
nucleotide regulatory proteins of the G-protein; STE4, a functional G-protein in yeast 
(Saccaromyces cerevisiae); CD4, a component of the yeast nuclear cytoskeleton; 
CDC20; Enhancer of Split, the product of one of the neurogenic genes in Drosophila; 
PRP17, a protein involved in pre-mRNA splicing and AET2/TUP1 a transcriptional 
repressor (van der Voon and Ploegh, 1992). 
 
STE4 is reported to be involved in a signal pathway that controls the response to 
mating pheromone. Moreover, CDC4 and CDC20 are required at the late G1/S phase 
boundary of the cell cycle and several microtubule-dependent processes at multi-
stages in the cell cycle respectively. 
 
Taking into consideration the involvement of the WD40 repeats in wide variety of 
cellular processes in eukaryotes its functions were deduced to be implicated in signal 
transduction, transcription, RNA processing, regulation in cell cycle and apoptosis 
(Saeki et al., 2006). The gene that encodes the G protein ß3 subunit
 
(GNB3) has also 
been reported to have a polymorphism (C825T) which has been associated with 
obesity and the variations of blood pressure causing hypertension (Rosskopf et al., 
2000). However the association or relationship between obesity, hypertension and the 
G-protein was not reported. 
  
To gain insight and knowledge into the structure of Tbl3, using SWISS-MODELLER, 
a 3-dimensional model of Tbl3 was generated based on its homology to 1pguA from 
Caenorhabditis elegans and Saccaromyces cerevisiae. The modelled structure was a 
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nine-helix bundle. Evaluation of the model was carried out using RAMPAGE to 
check for possible errors in protein stereochemistry. The structure was confirmed to 
have a high number of loop regions indicated by the 6 % that fell within disallowed 
regions. 
 
The study has a number of implications. The identified differential protein, Tbl3, can 
serve as a possible indicator of obesity or early stage diabetes, thus making it a 
potential biomarker. The Tbl3 can also be used in the development of lateral flow 
devices. This can assist in the design of diagnostic kits that would provide a point of 
care testing which promises the delivery of early and rapid diagnosis of prediabetes. 
The early diagnosis of diseases would allow for the monitoring of diseases and early 
efficient delivery of treatment for diseases. The knowledge of the structure might 
assist with the design and development of new drugs that may target obesity and 
possibly prediabetes. 
 
In conclusion, the identification of protein changes between the lean and obese rats 
using 2D gel electrophoresis and mass spectrometry has been possible. The 
applications of these techniques on urine have led to the identification of Tbl3 as a 
potential biomarker although much work still has to be done in order to validate this.  
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6.1 ADDRESSESS OF SUPPLIERS 
 
Applied Biosystems Inc. 
850 Lincoln Centre Drive 
Foster City, CA 94404  
USA 
Bayer AG 
51368 Leverkusen, Germany 
Phone: ++49 214 30-1 
 
Bio-Rad Laboratories Ltd. 
Life Science (Research, Education, Process Separations, Food/Animal/Environment 
Testing) 
34 Bolton Road 
Rosebank 
Johannesburg 2195 
P.O. Box 2884 
Parklands 2121 
Phone: +27 0861 246 723 
Fax: +27 11 327 2954 
E-mail: safrica_helpdesk@bio-rad.com 
 
Epol 
www.epol.co.za  
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Olympus digital camera 
Digital Cameras, Binoculars, Professional Imaging 
Tudor 
4th Floor, Park on Long, 66 Long Street 
8001 Cape Town  
Tel. +27 21 4242978 
Fax +27 21 4221534  
Email: info@tudortech.co.za 
 
Sigma-Aldrich / Fluka / Riedel-de Haën 
Box 14508, St. Louis 
Missouri 63178, USA 
www.sigma-aldrich.com 
 
Stuart scientific 
Bibby Scientific Limited, Beacon Road, Stone, Staffordshire ST15 0SA, UK 
Telephone: +44 (0) 1785 812121 Fax: +44(0) 1785 810405 
Email: info@bibby-scienific.com  
 
Whitehead scientific 
Tel: Cape Town 021 944 6460 or Johannesburg 011 894 2214  
Fax: Cape Town 021 949 5478 or Johannesburg 011 894 4583 
e-mail: whitesci@whitesci.co.za 
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Thermoservant GMI, Inc. 
6511 Bunker Lake Blvd.   
Ramsey, Minnesota, 55303, USA 
 
 
 
 
 
